Ali Sarram, MD
Urology · Lone Tree, CONPI 1043213929
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Teleflex LLC at 46.9% of the total. Reporting peaked in 2024 at $23,149 and has fallen 84.5% since, to $3,598 in 2025. Among urology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $332.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$35K
- Procept Biorobotics Corporation$35K
- Ferring Pharmaceuticals Inc.$1K
- Boston Scientific$628
- Covidien LP$625
- Astellas Pharma US Inc$521
- plus $2K from 31 others
What the payments were for
- Consulting fees$34,36445%
- Speaking & faculty fees$32,67043%
- Travel & lodging$2,4913%
- Food & beverage$6,0078%
- Education$2210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 60 | $35,491 |
| Procept Biorobotics Corporation | 38 | $35,221 |
| Ferring Pharmaceuticals Inc. | 4 | $1,156 |
| Boston Scientific | 13 | $628 |
| Covidien LP | 1 | $625 |
| Astellas Pharma US Inc | 24 | $521 |
| AbbVie(2 entities) | 21 | $340 |
| Olympus America Inc. | 6 | $255 |
| Johnson & Johnson | 1 | $149 |
| Pfizer | 5 | $101 |
| Comsort, Inc | 1 | $100 |
| Axonics, Inc. | 4 | $100 |
| Sumitomo Pharma America, Inc. | 4 | $98 |
| Tolmar, Inc. | 5 | $94 |
| Merck | 3 | $78 |
| Rochester Medical Corporation | 4 | $75 |
| Antares Pharma, Inc. | 4 | $72 |
| Dendreon Pharmaceuticals LLC | 2 | $69 |
| Endo Pharmaceuticals Inc. | 4 | $64 |
| Lumenis, Inc | 1 | $63 |
| AstraZeneca | 3 | $57 |
| Agiliti Surgical, Inc. | 2 | $47 |
| Blue Earth Diagnostics | 2 | $34 |
| SRS Medical Systems, Inc. | 1 | $30 |
| Urogen Pharma, Inc. | 2 | $27 |
| ABC Home Medical Supply, Inc. | 1 | $26 |
| Telix Pharmaceuticals | 1 | $24 |
| Myriad Genetic Laboratories, Inc. | 2 | $23 |
| KARL Storz Endoscopy-america | 1 | $23 |
| Endo USA, Inc. | 1 | $23 |
| Bayer | 1 | $21 |
| Myovant Sciences Inc. | 1 | $21 |
| Dentsply IH AB | 1 | $20 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $20 |
| 180 Medical, Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$33,141
- AQUABEAM SYSTEM$21,060
- AquaBeam Robotic System$13,686
- UroLift$1,295
- ADSTILADRIN$1,089
- Sonicision$625
- Erleada$149
- Axonics$136
- iTIND System$122
- GENERAL ONCOLOGY$119
- SpaceOAR VUE System - 10mL$119
- KEYTRUDA$100
How this compares
$75,753 in reported general payments places this provider in the 95th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 16 | $40,460 |
| GemtesaVibegron | 30 | $16,757 |
| Tamsulosin Hcl | 454 | $5,002 |
| Finasteride | 217 | $2,725 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 68 | $1,393 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 11 | $986 |
| Dutasteride | 21 | $745 |
| Testosterone Cypionate | 11 | $323 |
| Ciprofloxacin Hcl | 29 | $64 |
| Diazepam | 19 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $98 | $57,21746 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 urology providers in Colorado.
Other urology in Lone Tree
- Suzanne MerrillLone Tree$102K
- Jason GreenfieldLone Tree$19K
- Lawrence KarshDenver$706K
- Alexandra RogersLafayette$476K
- Derek ZukoskyGolden$442K
- James McBrideDurango$234K
- Damian SorceParker$224K
- John KeferBoulder$68K
- Garrick GreearLongmont$62K
- Nicholas WestfallGrand Junction$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.